Замена электродвигателя ПЭН турбоприводом на Кемеровской ТЭЦ

В данной работе рассматривается возможность замены электродвигателя ПЭН турбоприводом на Кемеровской ТЭЦ, с установкой турбопривода на существующий фундамент. Целью работы является оценка возможности увеличения отпуска электроэнергии от станции в результате уменьшения затрат на собственные нужды и повышение маневренности ТЭЦ.In this paper we consider the possibility of replacing the turbine drive motor PEN to Kemerovo CHP , with the installation of turbine drive on the existing foundation. The aim is to assess the possibility of increasing the supply of electric power from the plant by reducing the costs of their own needs and improving maneuverability CHP

Wildfire monitoring via the integration of remote sensing with innovative information technologies

In the Institute for Space Applications and Remote Sensing of the National Observatory of Athens (ISARS/NOA) volumes of Earth Observation images of different spectral and spatial resolutions are being processed on a systematic basis to derive thematic products that cover a wide spectrum of applications during and after wildfire crisis, from fire detection and fire-front propagation monitoring, to damage assessment in the inflicted areas. The processed satellite imagery is combined with auxiliary geo-information layers, including land use/land cover, administrative boundaries, road and rail network, points of interest, and meteorological data to generate and validate added-value fire-related products. The service portfolio has become available to institutional End Users with a mandate to act on natural disasters and that have activated Emergency Support Services at a European level in the framework of the operational GMES projects SAFER and LinkER. Towards the goal of delivering integrated services for fire monitoring and management, ISARS/NOA employs observational capacities which include the operation of MSG/SEVIRI and NOAA/AVHRR receiving stations, NOA's in-situ monitoring networks for capturing meteorological parameters to generate weather forecasts, and datasets originating from the European Space Agency and third party satellite operators. The qualified operational activity of ISARS/NOA in the domain of wildfires management is highly enhanced by the integration of state-of-the-art Information Technologies that have become available in the framework of the TELEIOS (EC/ICT) project. TELEIOS aims at the development of fully automatic processing chains reliant on a) the effective storing and management of the large amount of EO and GIS data, b) the post-processing refinement of the fire products using semantics, and c) the creation of thematic maps and added-value services. The first objective is achieved with the use of advanced Array Database technologies, such as MonetDB, to enable efficiency in accessing large archives of image data and metadata in a fully transparent way, without worrying for their format, size, and location, as well as efficiency in processing such data using state-of-the-art implementations of image processing algorithms expressed in a high-level Scientific Query Language (SciQL). The product refinement is realized through the application of update operations that incorporate human evidence and human logic, with semantic content extracted from thematic information coming from auxiliary geo-information layers and sources, for reducing considerably the number of false alarms in fire detection, and improving the credibility of the burnt area assessment. The third objective is approached via the combination of the derived fire-products with Linked Geospatial Data, structured accordingly and freely available in the web, using Semantic Web technologies. These technologies are built on top of a robust and modular computational environment, to facilitate several wildfire applications to run efficiently, such as real-time fire detection, fire-front propagation monitoring, rapid burnt area mapping, after crisis detailed burnt scar mapping, and time series analysis of burnt areas. The approach adopted allows ISARS/NOA to routinely serve requests from the end-user community, irrespective of the area of interest and its extent, the observation time period, or the data volume involved, granting the opportunity to combine innovative IT solutions with remote sensing techniques and

Operational Wildfire Monitoring and Disaster Management Support Using State-of-the-art EO and Information Technologies

Fires have been one of the main driving forces in the evolution of plants and ecosystems, determining the current structure and composition of the Landscapes. However, significant alterations in the fire regime have occurred in the recent decades, primarily as a result of socioeconomic changes, increasing dramatically the catastrophic impacts of wildfires as it is reflected in the increase during the 20th century of both, number of fires and the annual area burnt. Therefore, the establishment of a permanent robust fire monitoring system is of paramount importance to implement an effective environmental management policy. Such an integrated system has been developed in the Institute for Space Applications and Remote Sensing of the National Observatory of Athens (ISARS/NOA). Volumes of Earth Observation images of different spectral and spatial resolutions are being processed on a systematic basis to derive thematic products that cover a wide spectrum of applications during and after wildfire crisis, from fire detection and fire-front propagation monitoring, to damage assessment in the inflicted areas. The processed satellite imagery is combined with auxiliary geo-information layers and meteorological data to generate and validate added-value fire-related products. The service portfolio has become available to institutional End Users with a mandate to act on natural disasters in the framework of the operational GMES projects SAFER and LinkER addressing fire emergency response and emergency support needs for the entire European Union. Towards the goal of delivering integrated services for fire monitoring and management, ISARS/NOA employs observational capacities which include the operation of MSG/SEVIRI and NOAA/AVHRR receiving stations, NOA’s in-situ monitoring networks for capturing meteorological parameters to generate weather forecasts, and datasets originating from the European Space Agency and third party satellite operators. The qualified operational activity of ISARS/NOA in the domain of wildfires management is highly enhanced by the integra

Real-Time Wildfire Monitoring Using Scientific Database and Linked Data Technologies

We present a real-time wildfire monitoring service that exploits satellite images and linked geospatial data to detect hotspots and monitor the evolution of fire fronts. The service makes heavy use of scientific database technologies (array databases, SciQL, data vaults) and linked data technologies (ontologies, linked geospatial data, stSPARQL) and is implemented on top of MonetDB and Strabon. The service is now operational at the National Observatory of Athens and has been used during the previous summer by emergency managers monitoring wildfires in Greece

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

This multicenter phase II study evaluated, in chemonaive patients with stage IIIB–IV NSCLC, age ⩾70 and with a performance status 0–2, the activity, efficacy and tolerability of planned sequential administration of gemcitabine 1200 mg m−2 on days 1 and 8 every 3 weeks for three courses followed by three cycles of docetaxel 37.5 mg m−2 on days 1 and 8 every 3 weeks, provided there was no evidence of disease progression. A total of 56 patients entered the study. According to intention-to-treat analysis, the objective response rate was 16.0% (95% CI 7.6–28.3%); 23 patients (41.0%) had stable disease and 24 patients (43%) had progressive disease. Five patients who had a stable disease after three courses of gemcitabine obtained a conversion to partial response by docetaxel. Median time to progression was 4.8 months (95% CI 3.6–6.0 months) and median duration of survival was 8.0 months (95% CI 5.6–10.5 months). The 1-year survival rate was 34%. No grade 4 haematological toxicity was observed and grade 3 neutropenia and thrombocytopenia were reported in 5.4 and 3.6% of the patients, respectively. Grade 3/4 mucositis and grade 3 diarrhoea, both occurred in 3.6% of the patients and grade 3 asthenia was observed in 9% of patients. One patient reported a grade 4 skin toxicity. No treatment-related deaths occurred. Sequential gemcitabine and docetaxel is a well-tolerated and effective regimen in elderly advanced NSCLC patients

Bone growth during rapamycin therapy in young rats

<p>Abstract</p> <p>Background</p> <p>Rapamycin is an effective immunosuppressant widely used to maintain the renal allograft in pediatric patients. Linear growth may be adversely affected in young children since rapamycin has potent anti-proliferative and anti-angiogenic properties.</p> <p>Methods</p> <p>Weanling three week old rats were given rapamycin at 2.5 mg/kg daily by gavage for 2 or 4 weeks and compared to a Control group given equivalent amount of saline. Morphometric measurements and biochemical determinations for serum calcium, phosphate, iPTH, urea nitrogen, creatinine and insulin-growth factor I (IGF-I) were obtained. Histomorphometric analysis of the growth plate cartilage, in-situ hybridization experiments and immunohistochemical studies for various proteins were performed to evaluate for chondrocyte proliferation, chondrocyte differentiation and chondro/osteoclastic resorption.</p> <p>Results</p> <p>At the end of the 2 weeks, body and tibia length measurements were shorter after rapamycin therapy associated with an enlargement of the hypertrophic zone in the growth plate cartilage. There was a decrease in chondrocyte proliferation assessed by <it>histone-4 </it>and <it>mammalian target of rapamycin </it>(<it>mTOR</it>) expression. A reduction in <it>parathyroid hormone/parathyroid hormone related peptide (PTH/PTHrP) </it>and an increase in <it>Indian hedgehog </it>(<it>Ihh</it>) expression may explain in part, the increase number of hypertrophic chondrocytes. The number of TRAP positive multinucleated chondro/osteoclasts declined in the chondro-osseous junction with a decrease in the <it>receptor activator of nuclear factor kappa β ligand </it>(<it>RANKL</it>) and <it>vascular endothelial growth factor </it>(<it>VEGF</it>) expression. Although body and tibial length remained short after 4 weeks of rapamycin, changes in the expression of chondrocyte proliferation, chondrocyte differentiation and chondro/osteoclastic resorption which were significant after 2 weeks of rapamycin improved at the end of 4 weeks.</p> <p>Conclusion</p> <p>When given to young rats, 2 weeks of rapamycin significantly decreased endochondral bone growth. No catch-up growth was demonstrated at the end of 4 weeks, although markers of chondrocyte proliferation and differentiation improved. Clinical studies need to be done to evaluate these changes in growing children.</p

Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol

<p>Abstract</p> <p>Background</p> <p>Adjuvant chemotherapy has been proven to be beneficial for patients with early stage non-small cell lung cancer. However, toxicity and insufficient dose delivery have been critical issues with the chemotherapy used. Doublet regimens with pemetrexed, a multi-target folate inhibitor, and platin show clear activity in non-small cell lung cancer and are well tolerated with low toxicity rates and excellent delivery.</p> <p>Methods/Design</p> <p>In this prospective, multi-center, open label randomized phase II study, patients with pathologically confirmed non-small cell lung cancer, stage IB, IIA, IIB, T3N1 will be randomized after complete tumor resection either to 4 cycles of the standard adjuvant vinorelbine and cisplatin regimen from the published phase III data, or to 4 cycles of pemetrexed 500 mg/m2 d1 and cisplatin 75 mg/m2 d1, q 3 weeks. Primary objective is to compare the clinical feasibility of these cisplatin doublets defined as non-occurrence of grade 4 neutropenia and/or thrombocytopenia > 7 days or bleeding, grade 3/4 febrile neutropenia and/or infection, grade 3/4 non-hematological toxicity, non-acceptance leading to premature withdrawal and no cancer or therapy related death. Secondary parameters are efficacy (time to relapse, overall survival) and drug delivery. Parameters of safety are hematologic and non-hematologic toxicity of both arms.</p> <p>Discussion</p> <p>The TREAT trial was designed to evaluate the clinical feasibility, i.e. rate of patients without dose limiting toxicities or premature treatment withdrawal or death of the combination of cisplatin and pemetrexed as well as the published phase III regimen of cisplatin and vinorelbine. Hypothesis of the study is that reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and perhaps survival.</p> <p>Trial Registration</p> <p>Clinicaltrials.gov NCT00349089</p

Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)

To evaluate the efficacy and toxicity of the sequential nonplatinum combination chemotherapy consisting of gemcitabine (GEM) and vinorelbine (VNR) followed by docetaxel (DOC) in patients with advanced non-small-cell lung cancer (NSCLC), we conducted the multiinstitutional phase II study. A total of 44 chemotherapy-naive patients with advanced NSCLC were treated with GEM 1000 mg m−2 and VNR 25 mg m−2 intravenously on days 1 and 8 every 3 weeks for three cycles. DOC 60 mg m−2 was then administrated intravenously at 3-week intervals for three cycles. Patients were evaluated for response and toxicity with each cycle of the treatment. The major objective response rate was 47.7% (95% confidence interval (CI), 33.8–62.1%). Median survival time (MST) was 15.7 months and 1-year survival rate was 59%. In the GEM/VNR cycle, grade 3/4 neutropenia occurred in 36.3%, grade 3/4 anaemia in two patients (4.5%) and grade 3 thrombocytopenia in one patient (2.3%). Grade 3 pneumonitis occurred in two patients (4.5%) in GEM/VNR cycles. In the DOC cycles, grade 3/4 neutropenia occurred in 39.4% but no patient experienced grade 3/4 anaemia or thrombocytopenia. Of the 44 eligible patients, 33 patients completed three cycles of GEM/VNR and 22 patients completed six cycles of planned chemotherapy (three cycles of GEM/VNR followed by three cycles of DOC). The sequential triplet nonplatinum chemotherapy consisted of GEM/VNR followed by DOC, and was very active and well tolerated. This study forms the basis for an ongoing phase III trial that compares this nonplatinum triplet and standard platinum doublet combination (carboplatin/paclitaxel)

Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours

The aim of this open-label phase 1b study was to assess the safety and pharmacokinetics of motesanib in combination with gemcitabine in patients with advanced solid tumours. Eligible patients with histologically or cytologically documented solid tumours or lymphoma were enroled in three sequential, dose-escalating cohorts to receive motesanib 50 mg once daily (QD), 75 mg two times daily (BID), or 125 mg QD in combination with gemcitabine (1000 mg m−2). The primary end point was the incidence of dose-limiting toxicities (DLTs). Twenty-six patients were enroled and received motesanib and gemcitabine. No DLTs occurred. The 75 mg BID cohort was discontinued early; therefore, 125 mg QD was the maximum target dose. Sixteen patients (62%) experienced motesanib-related adverse events, most commonly lethargy (n=6), diarrhoea (n=4), fatigue (n=3), headache (n=3), and nausea (n=3). The pharmacokinetics of motesanib and of gemcitabine were not markedly affected after combination therapy. The objective response rate was 4% (1 of 26), and 27% (7 of 26) of patients achieved stable disease. In conclusion, treatment with motesanib plus gemcitabine was well tolerated, with adverse event and pharmacokinetic profiles similar to that observed in monotherapy studies